All Posts
#ESCCongress – Meta-analysis of randomized trials | SGLT-2 inhibitors in patients with heart failure.
29 Aug, 2022 | 12:35h | UTCSGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials – The Lancet (free registration required)
Commentary on Twitter
Our meta-analysis of SGLT2 inhibitors in HF is now online in @TheLancet showing a
consistent reduction in the risk of CV death and HF hospitalisation in a broad range of 21,947
patients across range of EF and in different care settingshttps://t.co/qnxgayR235 pic.twitter.com/x0RsINoE9y— Kieran Docherty (@Kieranfdocherty) August 27, 2022
#ESCCongress – RCT | Dapagliflozin reduced the risk of worsening heart failure or cardiovascular death in patients with heart failure with mildly reduced or preserved ejection fraction.
29 Aug, 2022 | 12:36h | UTCDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Dapagliflozin benefits patients with mildly reduced and preserved ejection fraction – European Society of Cardiology
Related (#ESCCongress 2021): RCT: SGLT2 inhibition reduced the combined risk of cardiovascular death or hospitalization in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.
Commentary on Twitter
DELIVER: In an RCT involving patients with HF and a mildly reduced or preserved ejection fraction, dapagliflozin reduced the risk of the composite outcome of worsening heart failure or CV death. #ESCCongress https://t.co/0umSDn5HkO pic.twitter.com/nq7zD2Fi2K
— NEJM (@NEJM) August 27, 2022
#ESCCongress – RCT | In patients with rheumatic heart disease–associated atrial fibrillation, treatment with a Vitamin K antagonist led to a lower rate of cardiovascular events or death compared to Rivaroxaban.
29 Aug, 2022 | 12:33h | UTCRivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Trial backs standard of care for rheumatic heart disease and atrial fibrillation – European Society of Cardiology
Commentary: INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF – TCTMD
Commentary on Twitter
INVICTUS: In patients with RHD-associated AF, compared to rivaroxaban, VKA reduced cardiovascular events and mortality without increasing bleeding. #ESCCongress https://t.co/4C45LmmB5o pic.twitter.com/9n3OelzZvp
— NEJM (@NEJM) August 28, 2022
[News release – not published yet] #ESCCongres – RCT | Evening dosing of blood pressure medication not better than morning dosing.
29 Aug, 2022 | 12:30h | UTCRelated Consensus Statement: Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension – Journal of Hypertension
Related study (conflicting results): Bedtime Hypertension Treatment Improves Cardiovascular Risk Reduction in Randomized Trial
#ESCCongress – RCT | Routine functional testing is not better than standard care in high-risk patients after percutaneous coronary intervention.
29 Aug, 2022 | 12:32h | UTCRoutine Functional Testing or Standard Care in High-Risk Patients after PCI – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
POST-PCI: In a randomized trial of patients who underwent percutaneous coronary intervention, routine stress testing did not improve clinical outcomes at two years. #ESCCongress https://t.co/nil00HQm4Z pic.twitter.com/o4v0UcDfYV
— NEJM (@NEJM) August 28, 2022
Bedtime dosing of antihypertensive medications: systematic review and consensus statement. – “use of bedtime drug dosing of antihypertensive drugs should not be routinely recommended”.
29 Aug, 2022 | 12:28h | UTC
RCT | Acetazolamide resulted in faster decongestion in patients with acute decompensated heart failure with volume overload.
29 Aug, 2022 | 12:25h | UTCAcetazolamide in Acute Decompensated Heart Failure with Volume Overload – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Acetazolamide improves decongestion in patients with acute decompensated heart failure – European Society of Cardiology
Commentary: Acetazolamide in Decompensated Heart Failure With Volume Overload – ADVOR – American College of Cardiology
Commentary on Twitter
https://twitter.com/NEJM/status/1563421082505588738
#ESCCongress | In patients within 6 months of a myocardial infarction, a polypill containing aspirin, ramipril, and atorvastatin resulted in a lower risk of major adverse cardiovascular events compared to usual care.
29 Aug, 2022 | 12:27h | UTCPolypill Strategy in Secondary Cardiovascular Prevention – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Polypill reduces cardiovascular events in heart attack patients compared to usual care – European Society of Cardiology
Commentaries:
Polypill Strategy Lowers Adverse CV Event Risk in Secondary Prevention – HCPLive
Related: M-A: Polypills with and without aspirin substantially reduce cardiovascular disease, myocardial infarction, stroke, revascularization, and cardiovascular death in primary cardiovascular disease prevention. (several studies on the subject)
#ESCCongress | 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.
29 Aug, 2022 | 12:21h | UTCNews Release: People of all ages should learn cardiopulmonary resuscitation – European Society of Cardiology
#ESCCongress | 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery.
29 Aug, 2022 | 12:22h | UTCNews Release: All patients over 65 years should have a heart check before high-risk non-cardiac surgery – European Society of Cardiology
#ESCCongress – RCT | A large study with 46.611 individuals between 65 and 74 years of age found that a comprehensive cardiovascular screening program did not significantly reduce the incidence of death from any cause.
29 Aug, 2022 | 12:24h | UTCFive-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Cardiovascular screening may reduce risk of death and cardiovascular disease – European Society of Cardiology
Commentary on Twitter
DANCANVAS: In men age 65-74 years in Denmark, those randomized to invitation to comprehensive screening for subclinical CVD did not have signif reduced all-cause mortality at median 5.6 yrs of follow-up. #ESCCongress https://t.co/YZL87aTVHR pic.twitter.com/HfdiNuU9sK
— NEJM (@NEJM) August 27, 2022
#ESCCongress | 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
29 Aug, 2022 | 12:18h | UTCNews Release: Pulmonary hypertension guidelines call for earlier diagnosis – European Society of Cardiology
#ESCCongress | 2022 ESC Guidelines on cardio-oncology.
29 Aug, 2022 | 12:17h | UTCNews Release: Advice to prevent heart problems caused by cancer therapy published today – European Society of Cardiology
Related guidelines:
Brazilian Cardio-oncology Guideline – 2020 – Arquivos Brasileiros de Cardiologia
#ESCCongress – RCT | In comatose survivors of out-of-hospital cardiac arrest, targeting a mean arterial blood pressure of 77 mmHg vs. 63 mmHg did not result in different outcomes.
29 Aug, 2022 | 12:13h | UTCBlood-Pressure Targets in Comatose Survivors of Cardiac Arrest – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Trial finds no benefit of raising blood pressure target in post cardiac arrest patients – European Society of Cardiology
Commentary: Blood Pressure Targets Show No Benefit in Comatose Survivors of Cardiac Arrest – HCPLive
Commentary on Twitter
BOX BP: This randomized trial found no difference in the rate of death or severe disability/coma when patients following out-of-hospital cardiac arrest were managed with higher or lower blood pressure targets. #ESCCongress https://t.co/5qOMtiPSck pic.twitter.com/QOl5KetTvn
— NEJM (@NEJM) August 27, 2022
RCT | Cemiplimab plus chemotherapy vs. chemotherapy alone in non-small cell lung cancer.
29 Aug, 2022 | 12:08h | UTC
Commentary on Twitter
Results from EMPOWER-Lung 3 demonstrate increased overall survival with #cemiplimab plus platinum-doublet #chemotherapy compared with cemiplimab as first-line treatment in patients with advanced non-small cell #LungCancer, irrespective of #PD-L1 expressionhttps://t.co/ojCDeivKzC
— Nature Medicine (@NatureMedicine) August 25, 2022
[News release – not published yet] #ESCCongress – RCT | Allopurinol does not improve cardiovascular outcomes in ischemic heart disease patients.
29 Aug, 2022 | 12:15h | UTCCommentary:
ALL-HEART: Gout Drug Allopurinol No Help in CV Prevention – TCTMD
No improvement with allopurinol for patients with ischemic heart disease: ALL-HEART – Cardiology Now
#ESCCongress – RCT | In comatose survivors of out-of-hospital cardiac arrest, a restrictive vs. a liberal oxygenation strategy resulted in similar incidences of death, severe disability, and coma.
29 Aug, 2022 | 12:12h | UTCOxygen Targets in Comatose Survivors of Cardiac Arrest – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Restrictive oxygenation in post cardiac arrest patients is not harmful – European Society of Cardiology
Commentary on Twitter
BOX Oxygen: This RCT found no difference in the rate of death or severe disability/coma when mechanically ventilated patients following out-of-hospital cardiac arrest were managed with higher or lower oxygenation targets. #ESCCongress https://t.co/qqtd4SyVrl pic.twitter.com/q73gqSuAn4
— NEJM (@NEJM) August 27, 2022
#ESCCongress – Single-arm study | Efficacy and safety of an extravascular implantable cardioverter–defibrillator.
29 Aug, 2022 | 12:09h | UTCEfficacy and Safety of an Extravascular Implantable Cardioverter–Defibrillator – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
EV ICD: Extravascular ICD can be implanted safely and can detect and terminate induced ventricular arrhythmias at the time of implant. #ESCCongress https://t.co/Th9evkPcIu pic.twitter.com/qWEcM8MggT
— NEJM (@NEJM) August 28, 2022
Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK.
29 Aug, 2022 | 12:11h | UTCAutoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK – The Lancet (free registration required)
Commentary: Population-based study: Autoimmune disorders increase risk of cardiovascular disease – MedicalXpress
Meta-analysis of randomized trials | Use of dexmedetomidine in patients with sepsis.
29 Aug, 2022 | 12:08h | UTC
M-A | Adverse pregnancy and birth outcomes associated with Mycoplasma hominis, Ureaplasma urealyticum and Ureaplasma parvum.
29 Aug, 2022 | 12:06h | UTC
Prevalence of multiple non-communicable diseases risk factors among adolescents in 140 countries: a population-based study.
29 Aug, 2022 | 12:04h | UTC
Commentary on Twitter
Our study shows that a large proportion of adolescents in all countries are exposed to four or more NCD risk factors, irrespective of region. Insufficient vegetable and fruit consumption, sedentary behaviour and physical inactivity were most prevalent. https://t.co/NKz2VXTiYG pic.twitter.com/E0fM7h7fRz
— M Mamun Huda (@mmamunhuda) August 13, 2022
RCT | Sacituzumab Govitecan in hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer.
29 Aug, 2022 | 12:05h | UTC
Meta-analysis of randomized trials | Intensive vs. short face-to-face smoking cessation interventions.
29 Aug, 2022 | 12:03h | UTC
Systematic Review | There is little evidence to guide interventions for preventing and reducing the use of physical restraints on older people in general hospital settings.
29 Aug, 2022 | 12:01h | UTC